scispace - formally typeset
Open AccessJournal ArticleDOI

Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases

Reads0
Chats0
TLDR
Overall FCM was well tolerated in this pediatric population and appeared to be effective in correcting iron deficiency anemia.
Abstract
The treatment of iron deficiency anemia in children with inflammatory bowel disease is a particular challenge and often insufficient. Absorption of orally given iron may be impaired by intestinal inflammation and treatment with oral iron may aggravate intestinal inflammation. This retrospective study is the first to describe the use of intravenous ferric carboxymaltose (FCM) in the pediatric setting. All subjects who had received at least one dose of FCM intravenously in the observation period were included in this analysis with data collected for up to 3 months post last FCM dose. In total, 72 children between 0 and 18 years with underlying gastrointestinal disorders had been treated for concomitant iron deficiency anemia. The majority of patients had Crohn’s disease (40.3%) or ulcerative colitis (30.5%). The total number of FCM administrations was 147, the mean number per patient was 2.0 and the mean cumulative dose 821 mg iron (median single dose: 500 mg; max. 1000 mg). Post administration of FCM, correction of iron deficiency anemia was observed with improved mean hemoglobin levels from 9.5 g/dL at baseline to 11.9 g/dL within 5–12 weeks. Decreases in white cell count, platelets and C-reactive protein were observed post FCM, potentially suggesting reduced inflammation with iron repletion. Three subjects reported mild adverse drug reactions related to FCM; two of these were considered to be potentially related to long duration of administration and to high volume of saline solution for dilution. As such, the method of administration was amended to have a maximum infusion time of 60 minutes and dilution with less than or equal to 100 mL saline solution. Overall FCM was well tolerated in this pediatric population and appeared to be effective in correcting iron deficiency anemia. We cannot exclude that the correction of iron deficiency anaemia is in some part due to the treatment of the underlying disease and not related to the iron supplementation only.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Ferric Carboxymaltose: A Review of Its Use in Iron Deficiency

TL;DR: Intravenous ferric carboxymaltose was generally well tolerated, with a low risk of hypersensitivity reactions, and was generally better tolerated than oral ferrous sulfate, mainly reflecting a lower incidence of gastrointestinal adverse effects.
Journal ArticleDOI

ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Iron and trace minerals.

TL;DR: The guidelines on pediatric parenteral nutrition were published by the ESPGHAN/ESPEN/ESPR/CSPEN guidelines as mentioned in this paper, which focused on iron and trace minerals.
Journal ArticleDOI

Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron

TL;DR: FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
Journal ArticleDOI

Advances in Pediatric Intravenous Iron Therapy.

TL;DR: It is suggested that front line use of IV iron should be strongly considered in diseases associated with IDA in children and the availability of newer IV iron products allows for replacement of the total iron deficit at a single setting.
References
More filters
Journal ArticleDOI

Long-Lasting Neural and Behavioral Effects of Iron Deficiency in Infancy

TL;DR: Evidence of long-term effects of iron deficiency in infancy and follow-up studies from preschool age to adolescence report poorer cognitive, motor, and social-emotional function, as well as persisting neurophysiologic differences.
Journal ArticleDOI

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.

TL;DR: FeCarb is effective and safe in IBD-associated anemia, and provides a fast Hb increase and a sufficient refill of iron stores, and is noninferior to FeSulf in terms of Hb change over 12 wk.
Journal ArticleDOI

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

TL;DR: The simpler FCM-based dosing regimen showed better efficacy and compliance, as well as a good safety profile, compared with the Ganzoni-calculated IS dose regimen.
Related Papers (5)